TGM2 and neoplasm: In breast cancer cells, TG2 overexpression conferred EMT and stem cell-like phenotypes, while IL-1β treatment increased stem cell-like phenotypes, cell invasion, and estrogen-independent tumor growth in a TG2-dependent manner; however, these effects were attenuated by treatment with either anti-IL-6 or anti-IL-1β antibodies.